LEARNING OBJECTIVES

- An increasing number of therapeutics that require biomarkers testing are available for clinical use or are in advanced phase of clinical development
- Different technologies can be used for biomarker testing depending on the nature of the biomarker and the availability of biological samples
- The increasing use of large panels for comprehensive genomic profiling raises issues on data interpretation that require a multidisciplinary approach
- Monitoring the molecular evolution of the disease might allow the identification of resistance mechanisms and the development of more effective therapeutic strategies
- The identification of germline variants requires the activation of genetic counselling programs for patients and their families

All timings are to be considered CET (Central European Time)

Thursday, 12 November 2020

15:00-15:05  Welcome and introduction

5’  Welcome and Learning Objectives Introduction, Fabrice André, FR and Nicola Normanno, IT

15:05-15:55  Session 1 – NGS comes to the clinic

20’  NGS for tissue biopsies, Reinhard Buettner, DE
20’  Technologies for the analysis of circulating DNA, Nicola Normanno, IT
10’  Discussion
15:55-17:10  **Session 2 – New technologies for precision medicine**
- 20’  Gene fusions, Caterina Marchiò, IT
- 20’  HRD testing, Lucy Yates, UK
- 20’  Single cell analyses: which impact in cancer research, Fabrice André, FR
- 15’  Discussion

17:10-17:25  **Coffee Break**

17:25-18:35  **Session 3 – Clinical implementation of NGS**
- 20’  Organization and role of the Molecular Tumour Board, Rodrigo Dienstmann, ES
- 20’  Incidental findings of NGS testing, Étienne Rouleau, FR
- 20’  The role of liquid biopsy in monitoring the response to treatment, Federica di Nicolantonio, IT
- 10’  Discussion

---

**Friday, 13 November 2020**

15:00-16:15  **Session 4 – Biomarkers for Immune checkpoint inhibitors**
- 20’  Molecular pathology, Paul Hofman, FR
- 20’  Genomic based assays, Albrecht Stenzinger, DE
- 20’  Emerging biomarkers, Rodrigo Dienstmann, ES
- 15’  Discussion

16:15-17:00  **Workshop 1**  
Which patients might benefit comprehensive genomic profiling? 
Rodrigo Dienstmann, ES and Fabrice André, FR  
15’  Introduction based on clinical cases presented by speakers  
30’  Discussion

17:00-17:15  **Coffee Break**

17:15-18:00  **Workshop 2**  
How to integrate liquid biopsy in the management of cancer patients? 
Nicola Normanno, IT and Federica di Nicolantonio, IT  
15’  Introduction based on clinical cases presented by speakers  
30’  Discussion

18:00-18:10  **Synthesis and wrap-up**